Jobs

Developing effective targeted and rational therapies against cancer cells is a challenging task given the substantial variations in molecular and cellular landscapes between and within tumors. Single-cell profiling approaches have advanced our understanding of the extent of cellular diversity in tumor ecosystem, and its role in immune evasion and tumor progression. A full-resolution understanding of these interactions and functional inter-dependencies between tumor cells and stromal constituents in tumor microenvironment (TME) will help uncover mechanisms that underlie immune evasion and therapy resistance in tumors, and will open new avenues for therapeutic innovations. Toward this goal, we dissect functional heterogeneity among cancer and stromal cells by investigating diversity in active gene expression patterns using single-cell RNA-seq (scRNA-seq). We also leverage the power of in situ spatial transcriptome and proteome profiling to elucidate cellular organization within tissues. This is critical for understanding the complex interplay between diverse cell types within tumors. By integrating the scRNA-seq data with spatial transcriptome profiles we aim to identify potential interactions and cellular inter-dependencies that fuel tumor progression and therapy resistance.

This research program is built on joint-forces from expert clinicians and scientists at McGill University Health Centre (MUHC), McGill Genome Centre (MGC) and Goodman Cancer Institute (GCI) to create a trans-disciplinary research program that leverages the expertise in genomics, computational science and statistics, cancer biology, histopathology, and cutting-edge tumor models to address the aforementioned unmet needs in order to improve patient survival and disease outcomes.

The Cardiology and Critical Care Research Program (C₃RP) at the Robarts Research Institute is located on the Western University campus and is connected to the London Health Sciences Center (LHSC). Under the supervision of two principal investigators (Dr. Aleks Leligdowicz and Dr. Mark Chandy), the laboratory employs novel multi-“omic” techniques to study biological samples from patients to understand disease mechanisms of early infection during critical illness and cardiovascular disease.

The main pillars of research are: (1)  the influence of innate and adaptive immune regulation and endothelial injury on outcomes in critical illness, and (2) the impact of environmental factors on the development of cardiovascular disease using induced pluripotent stem cells (iPSC). Advanced cell culture and gene editing in conjunction with imaging techniques (flow cytometry, microscopy), functional biological assays, and RNA-sequencing are used to address these research goals.

Our lab is seeking a talented and highly motivated postdoctoral associate with expertise in large-scale statistical analyses of clinical data and their integration with complex biological studies. Biological data types include RNA-Sequencing, cell imaging (flow cytometry, microscopy), proteomics, and clinical trial analysis.

The successful candidate will interact with local, national, and international experts in clinical bioinformatics, contribute to manuscript and grant preparation, and engage in supporting our research trainees.

Fixed Term 3 years – Full Time

A postdoctoral researcher is sought for a three-year post in the lab of Prof. Andrew Jackson FRS, to investigate the biological basis of indel cancer signatures.

The Opportunity:
Mutation underlies cancer development, genetic disease and evolution. Sequencing of cancer genomes has defined many mutational signatures, but for a substantial number the underlying mechanism is unknown. Linking such signatures to cellular pathways will be key for personalized medicine targeting future cancer therapy.

The purpose of this post is to use computational approaches harnessing large-scale whole genome sequencing (ICGC, GeL, others) and in house NGS datasets to understand mechanisms underlying indel mutational signatures. The successful applicant will investigate the role of transcription-associated mutagenesis and the ID4 cancer signature in cancer, to define when, where and how it occurs, extending recent lab discoveries (Reijns et al. Nature 2022). Alongside they will contribute to methodological innovations, including development of novel computational and experimental techniques for mutation detection.

The post-holder will be part of a multidisciplinary team, allowing their computational insights to be experimentally tested by wet-lab colleagues. They will also have the opportunity to contribute to the diversity of the lab’s research, ranging from human gene discovery, genome-wide CRISPR screens, epigenetic regulation of growth, and the cell biology of DNA replication and genome stability.

The research group is internationally diverse and strongly competitive with 12 papers published in Cell and Nature journals in the last 10 years.

A postdoctoral fellowship is available in the laboratories of Dr. Suzanne Trudel, MSc, MD, FRCPC and Dr. Trevor Pugh, PhD, FACMG at the Princess Margaret Cancer Centre / University Health Network in Toronto, Canada. Located in the MaRS Centre in the heart of the downtown Discovery District, we are an integral component of multiple translational genomics projects and platforms including the Cancer Genomics Program, Tumour Immunotherapy Program, Princess Margaret Genomics Centre, and the OICR Genomics Program. This position is an opportunity for a scientifically creative, computationally-inclined individual with a strong cancer biology background to further their understanding of therapeutic response and resistance mechanisms to immunotherapy as well as underlying oncogenic mechanisms active in the hematologic malignancy multiple myeloma.

If you are interested in the integration of multiomics data to understand gene regulation, the laboratory of Dr Steve Bilodeau is looking for postdoctoral candidates. Dr. Bilodeau’s team uses advanced technologies as well as computational biology to define the molecular mechanisms controlling gene expression during normal and disease development. Talented and creative candidates willing to challenge current dogmas are strongly encouraged to apply.

The Laboratory of Dr Steve Bilodeau is located at the Centre de Recherche du CHU de Québec – Université Laval in Québec City. The city is internationally recognized for its outstanding quality of life, lively cultural scene, and reasonable cost of living. In 2023, the oncology division and the team of Dr Bilodeau will move to a new cutting-edge research facility part of a new hospital complex currently in construction.